Joint presidents to run Wolters Kluwer analytics biz

Share this article:
Wolters Kluwer Pharma Solutions jointly appointed Bob Jansen and Michelle Woker as co-presidents of its analytics business.

Jansen and Woker will lead the commercial and operations functions, respectively. Their promotions follow the retirement of former Wolters Kluwer Pharma Solutions head Mark Spiers in April. Bob Becker, head of parent company Wolters Kluwer Health & Pharma Solutions, has been running the unit in the interim. The new leaders will report directly to him.

Jansen has been SVP, commercial operations, for Wolters Kluwer Pharma Solutions' healthcare analytics business since 2007. Prior to that, he had helped lead managed markets sales and contracting areas for a number of pharmaceutical companies. Woker has been with the healthcare analytics business for 17 years, most recently as SVP, operations.

Jansen and Woker are responsible for healthcare analytics only. The publishing side of the company is run by different leadership in place since prior to Spiers' departure. Wolters Kluwer Pharma Solutions is a unit of Wolters Kluwer Health & Pharma Solutions, a division of Wolters Kluwer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...